OMEPRAZOLE AND SODIUM BICARBONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omeprazole And Sodium Bicarbonate, and what generic alternatives are available?
Omeprazole And Sodium Bicarbonate is a drug marketed by Ajanta Pharma Ltd, Anda Repository, Aurobindo Pharma, Aurolife Pharma Llc, Chartwell Rx, Dr Reddys, Perrigo R And D, Sciegen Pharms Inc, Strides Pharma, Zydus, and Zydus Pharms. and is included in fifteen NDAs.
The generic ingredient in OMEPRAZOLE AND SODIUM BICARBONATE is omeprazole; sodium bicarbonate. There are one hundred and thirty-one drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the omeprazole; sodium bicarbonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Omeprazole And Sodium Bicarbonate
A generic version of OMEPRAZOLE AND SODIUM BICARBONATE was approved as omeprazole; sodium bicarbonate by STRIDES PHARMA on April 19th, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMEPRAZOLE AND SODIUM BICARBONATE?
- What are the global sales for OMEPRAZOLE AND SODIUM BICARBONATE?
- What is Average Wholesale Price for OMEPRAZOLE AND SODIUM BICARBONATE?
Summary for OMEPRAZOLE AND SODIUM BICARBONATE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 15 |
Finished Product Suppliers / Packagers: | 25 |
Clinical Trials: | 12 |
What excipients (inactive ingredients) are in OMEPRAZOLE AND SODIUM BICARBONATE? | OMEPRAZOLE AND SODIUM BICARBONATE excipients list |
DailyMed Link: | OMEPRAZOLE AND SODIUM BICARBONATE at DailyMed |
Recent Clinical Trials for OMEPRAZOLE AND SODIUM BICARBONATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Food and Drug Administration (FDA) | Phase 1 |
BioPharma Services, Inc | Phase 1 |
Ajou University School of Medicine | Phase 1 |
Pharmacology for OMEPRAZOLE AND SODIUM BICARBONATE
Drug Class | Proton Pump Inhibitor Osmotic Laxative |
Mechanism of Action | Alkalinizing Activity Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors Osmotic Activity |
Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |